Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Cardoso on the Rationale Behind the Global mBC Vision 2025 Call-to-Action

April 13th 2017

Fatima Cardoso, MD, coordinator, European School of Oncology Breast Cancer Program, Secretary General, European Organization for Research and Treatment of Cancer, director, Breast Unit, Campalimaud Clinical Cancer Center, discusses the rationale behind the Global mBC Vision 2025 Call-to-Action.

HER2-Enriched Subtype Predicts Response to Dual HER2 Blockade in Early Breast Cancer

April 10th 2017

According to results from the PAMELA trial, women with the HER2-enriched subtype of early-stage, HER2-positive breast cancer were more likely to have a pathological complete response when treated with dual HER2-blockade.

Tailoring Therapy for HR-Positive Breast Cancer

April 8th 2017

Experts discuss the most effective ways to use new targeted therapies for patients with advanced hormone receptor-positive breast cancer in an OncLive Peer Exchange® panel.

Novel HER2 Inhibitor May Help Treat Brain Tumors in Breast Cancer Patients

April 7th 2017

Investigators are seeking to determine whether adding tucatinib (ONT-380), a novel small-molecule HER2 inhibitor, to standard therapies will improve outcomes for patients with progressive metastatic HER2-positive breast cancer, including those with brain tumors.

Dr. Rugo Discusses MONARCH I in HR+ HER2- Breast Cancer

April 7th 2017

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer

April 5th 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

Dr. Huober on Selection Criteria for Adjuvant Systemic Therapy for Breast Cancer

April 3rd 2017

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses selection criteria for adjuvant systemic therapy for patients with breast cancer.

Atezolizumab Yields Long-Term OS in mTNBC Subset

April 3rd 2017

According to results presented at the 2017 AACR Annual Meeting, 10% of patients showed impressive long-term survival in a phase I study of single agent anti-PD-L1 atezolizumab (Tecentriq) in patients with metastatic triple-negative breast cancer.

Neratinib Shows Promise in HER2-Mutated Cancers

April 2nd 2017

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with HER2-mutant advanced cancers.

FDA Grants Full Approval to Frontline Palbociclib in Breast Cancer

April 1st 2017

The FDA has granted a full approval to palbociclib (Ibrance) for use in combination with letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

Hurvitz Discusses Debate Over Anthracycline Use in Breast Cancer

March 31st 2017

Sara A. Hurvitz, MD, discussed the use of anthracycline regimens in breast cancer during a talk at the 2017 Miami Breast Cancer Conference.

Overcoming Resistance to HER2-Targeted Therapy in Breast Cancer

March 29th 2017

Mark D. Pegram, MD, discusses resistance mechanisms being studied in the quest to overcome resistance to HER2-targeted therapy in breast cancer.

Expert Discusses State of Bone-Targeted Therapy in Breast Cancer

March 27th 2017

Adam M. Brufsky, MD, PhD, discusses considerations for using denosumab and zoledronic acid in patients with breast cancer.

Findings From the SystHERs Real-World Study of HER2+ Breast Cancer

March 27th 2017

Mohammad Jahanzeb, MD, discusses the SystHERs trial, which was designed to provide real-world insight into current treatment patterns, long-term survival, and patient experience with multiple different treatments for HER2-positive metastatic breast cancer.

Addressing Sexuality and Fertility Issues in Breast Cancer Patients

March 25th 2017

Leslie Schover, PhD, discusses strategies to help patients with breast cancer who have sexuality and fertility issues.

Dr. Osborne on the Benefits of Dual-Targeted Therapy for HER2+ Breast Cancer

March 25th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefits of dual-targeted therapy for patients with HER2-positive breast cancer.

Novel Approaches in Male Breast Cancer

March 24th 2017

Male breast cancer is a rare and poorly understood disease, but recent molecular studies have revealed fundamental differences from female breast cancer that could help guide treatment strategies toward a more tailored approach.

AR Emerges as a Potential Target in Triple-Negative Breast Cancer

March 24th 2017

Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.

Positive Immunotherapy Signals in TNBC Need Further Study

March 23rd 2017

Immune checkpoint inhibitors in triple-negative breast cancer are showing promise, but there must be future research to determine whether these agents can make a difference in this challenging malignancy.

Hurvitz Discusses Dramatic Advances in HER2+ Breast Cancer

March 23rd 2017

Sara Hurvitz, MD, discusses the amazing evolution in the available treatment options for patients with HER2-positive breast cancer.